Drug intelligence / Profile preview

BPI-004

Development stage: Preclinical
Lead developer: BeyondSpring
Modality: Small Molecules

Overview

BPI-004 is a small molecule developed by BeyondSpring Inc. It functions by inducing the production of neoantigens by tumor cells. This mechanism allows tumors that typically lack immune cell infiltration to become recognized by the immune system, thereby potentially making them responsive to immunotherapies such as PD-1 inhibitors. Many human cancers do not produce antigens that the immune system can recognize, rendering them unresponsive to immune checkpoint blockade. BPI-004 aims to overcome this resistance by making these "cold" tumors "hot" and susceptible to immune-mediated attack.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on BPI-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-004.

Explore the full profile